Overall survival analysis of lung cancer patients receiving pharmaceutical therapy revealed that the AKR1C1 high group presented a greater hazard ratio versus the AKR1C1 low group (Fig. S1B, C). This evidence concerns the gene AKR1C1 and lung carcinoma.